Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung cancer.
The role of adjuvant therapy in non-small-cell lung cancer continues to be defined. We review the most recent major reports of adjuvant trials. Three large randomized trials of postoperative chemotherapy and/or radiation therapy for stage I and II patients have noted improvement trends in median and long-term survival. Two large preoperative phase II trials for stage IIIA patients have reported high response and surgical resectability rates for preoperative combinations of radiation and chemotherapy, but without significant improvement in survival. In general, most of these protocols require months to complete, and not all patients are able to withstand the associated toxicity. The field of adjuvant therapy is continuing to develop; some of the strategies of ongoing protocols are reviewed.
Jaklitsch
M T
MT
Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA 02115.
Strauss
G M
GM
Sugarbaker
D J
DJ
D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic